Intelligence · Patents

Patents expiring in 2029

Annual patent cliff calendar for 2029 — US pharmaceutical patents by expiration date.

Patents
675

Quick answer

675 indexed pharmaceutical patents have expiration dates in 2029. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 7524507

    Recombinant microorganisms

    The Secretary of State for Defence in Her Brittanic Majesty's Government of the United Kingdom of Great Britain and Northern Ireland · Granted Tue Apr 28 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 7524499

    Modified chimeric polypeptides with improved pharmacokinetic properties

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 28 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 7524880

    Crystalline form of a substituted pyrrolidine compound

    Theravance, Inc. · Granted Tue Apr 28 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 7527786

    Methods for inhibiting the growth of cancer cells expressing PSCA

    The Regents of the University of California · Granted Tue May 05 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 7528202

    Poly (ethylene glycol) derivatives with proximal reactive groups

    Nektar Therapeutics AL, Corporation · Granted Tue May 05 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 7528138

    Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases

    Vertex Pharmaceuticals Incorporated · Granted Tue May 05 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 7527802

    Vaccine for transcutaneous immunization

    The United States of America as represented by the Secretary of the Army · Granted Tue May 05 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 7527934

    Labeled substrate conjugates for identifying enzyme inhibitors

    The Regents of the University of California · Granted Tue May 05 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 7527797

    Vibrio cholerae 0139 conjugate vaccines

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue May 05 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 7528118

    RNAi modulation of ApoB and uses thereof

    Alnylam Pharmaceuticals, Inc. · Granted Tue May 05 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 7528253

    Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity

    Theravance, Inc. · Granted Tue May 05 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. US 7528274

    Acylthiols and component thiol compositions as anti-HIV and anti-retroviral agents

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue May 05 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. US 7527952

    Crystals of inosine monophosphate dehydrogenase/oxidized inosine monophosphate thiomidate intermediate/mycophenolic acid (IIMPDH/XMP*/MPA)

    Vertex Pharmaceuticals Incorporated · Granted Tue May 05 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. US 7528142

    Aminopyrimidines useful as kinase inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Tue May 05 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  15. US 7528133

    Use of thiazolidinediones derivatives for preventing uterine contractions in premature labour or lactation

    The Board of Regents of the University of Texas System · Granted Tue May 05 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  16. US 7531523

    Sodium channel protein type III alpha-subunit splice variant

    Vertex Pharmaceuticals Incorporated · Granted Tue May 12 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  17. US 7531500

    Preventing airway mucus production by administration of EGF-R antagonists

    The Regents of the University of California · Granted Tue May 12 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  18. US 7531536

    Pyrazole compounds useful as protein kinase inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Tue May 12 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  19. US 7531556

    Compositions useful as inhibitors of rock and other protein kinases

    Vertex Pharmaceuticals Incorporated · Granted Tue May 12 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  20. US 7531570

    Treatment of diseases using ICE inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Tue May 12 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  21. US 7531623

    Hydrochloride salts of a glycopeptide phosphonate derivative

    Theravance, Inc. · Granted Tue May 12 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  22. US 7531635

    MATER-protein specific antibodies and methods of use

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue May 12 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  23. US 7531162

    Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation

    Regents of the University of Minnesota · Granted Tue May 12 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  24. US 7531656

    Synthesis of gatifloxacin

    Teva Pharmaceuticals USA, Inc. · Granted Tue May 12 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  25. US 7531341

    Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof

    BIOMARIN PHARMACEUTICAL INC. · Granted Tue May 12 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  26. US 7531514

    Orally administered peptides synergize statin activity

    The Regents of the University of California · Granted Tue May 12 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  27. US 7531355

    Methods and compositions for smooth muscle reconstruction

    The Regents of the University of California · Granted Tue May 12 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  28. US 7531352

    Inducible plasmid vector encoding TGF-β and use thereof

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue May 12 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  29. US 7531173

    Ophthalmic composition of a VEGF antagonist

    REGENERON PHARMACEUTICALS, INC. · Granted Tue May 12 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  30. US 7531172

    Methods of treating diseases with a VEGF antagonist

    REGENERON PHARMACEUTICALS, INC. · Granted Tue May 12 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  31. US 7534418

    Imaging agents

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue May 19 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 14 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  32. US 7534775

    Methods and compositions for modulating cardiac contractility

    Sangamo Biosciences, Inc. · Granted Tue May 19 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 14 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  33. US 7534887

    Thiazoline derivative and use of the same

    Takeda Pharmaceutical Company Limited · Granted Tue May 19 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 14 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  34. US 7534913

    Crystalline form of nateglinide

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue May 19 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 14 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  35. US 7534440

    Fusion molecules and methods for treatment of immune diseases

    The Regents of the University of California · Granted Tue May 19 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 14 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  36. US 7534900

    Process for the purification of duloxetine hydrochloride

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue May 19 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 14 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  37. US 7534859

    Protein kinase C epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse

    The Regents of the University of California · Granted Tue May 19 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 14 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  38. US 7534889

    5-HT4 receptor agonist compounds

    Theravance, Inc. · Granted Tue May 19 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 14 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  39. US 7534604

    Fusion polypeptides capable of activating receptors

    REGENERON PHARMACEUTICALS, INC. · Granted Tue May 19 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 14 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  40. US 7534764

    Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin

    The Regents of the University of California · Granted Tue May 19 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 14 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  41. US 7534761

    Charged peptide-amphiphile solutions and self-assembled peptide nanofiber networks formed therefrom

    Northwestern University · Granted Tue May 19 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 14 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  42. US 7534613

    Methods of treating parkinson's disease using viral vectors

    The Regents of the University of California · Granted Tue May 19 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 14 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  43. US 7534595

    Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof

    BIOMARIN PHARMACEUTICAL INC. · Granted Tue May 19 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 14 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  44. US 7534565

    DLC-1 gene deleted in cancers

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue May 19 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 14 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  45. US 7534868

    Human antibodies to human delta like ligand 4

    REGENERON PHARMACEUTICALS, INC. · Granted Tue May 19 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 14 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  46. US 7538125

    Pharmaceutical composition

    Takeda Pharmaceutical Company Limited · Granted Tue May 26 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 21 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  47. US 7537791

    Parthenolide free bioactive ingredients from feverfew (Tanacetum parthenium) and processes for their production

    INTEGRATED BOTANICAL TECHNOLOGIES, LLC · Granted Tue May 26 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 21 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  48. US 7537759

    Modulating angiogenesis

    The Regents of the University of California · Granted Tue May 26 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 21 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2029?

675 published patents in our USPTO index have expiration dates falling in calendar year 2029.